JenaValve
Irvine, US · 3 known investors
JenaValve manufactures the Trilogy Transcatheter Heart Valve System, an FDA-approved device for treating severe aortic regurgitation in high-risk patients who cannot undergo surgical valve replacement. The company develops minimally invasive cardiac medical devices and related delivery systems for interventional cardiology.
Founders & leadership
VC
Victoria Carr-BrendelExecutive
HF
Hans-Reiner FigullaNamed on SEC filing
DD
David DrachmanNamed on SEC filing
Board
AK
EA
Erik AmbleBoard director
PB
Peter BarrettBoard director
OL
Olivier LitzkaBoard director
OX
Ouyang XiangyuBoard director
PV
Patrick van BenedenBoard director
RC
Raymond CohenBoard director
JK
Jan KeltjensBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$315M disclosed across 8 rounds · 2013–2021
▶$100.4MraisedApr 2024 · 17 investors · Other Health CareRule 506(b)
▶$100.4MraisedApr 2024 · 17 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Daniel DearenDirector
- Jan KeltjensDirector
- John KilcoyneExecutive Officer, Director
- Andrew HackDirector
- Jan PensaertDirector
- Keith DawkinsDirector
- Olivier LitzkaDirector
- Kenneth MacLeodDirector
- Offering amount
- $100.4M
- Amount sold
- $100.4M
- Sales commissions
- $525K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66.5MraisedOct 2020 · 8 investors · Other Health CareRule 506(b)
▶$66.5MraisedOct 2020 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Andrew HackDirector
- Olivier LitzkaDirector
- Erik AmbleDirector
- Patrick van BenedenDirector
- Jose (Pepe) Calle GordoDirector
- Rudi MarienDirector
- Peter WulffExecutive Officer
- John KilcoyneExecutive Officer, Director
- Jan KeltjensDirector
- Keith DawkinsDirector
- Offering amount
- $66.5M
- Amount sold
- $66.5M
- Finders' fees
- $1.6M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.5MraisedJun 2019 · 10 investors · Other Health CareRule 506(b)
▶$14.5MraisedJun 2019 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John KilcoyneExecutive Officer, Director
- Jose Calle GordoDirector
- Peter WulffExecutive Officer
- Jan PensaertDirector
- Jan KeltjensDirector
- Keith DawkinsDirector
- Olivier LitzkaDirector
- Rudi MarienDirector
- Erik AmbleDirector
- Patrick van BenedenDirector
- Offering amount
- $14.5M
- Amount sold
- $14.5M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.3MraisedJul 2018 · 11 investors · Other TechnologyRule 506(b)
▶$14.3MraisedJul 2018 · 11 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Olivier LitzkaDirector
- Patrick van BenedenDirector
- Jan PensaertDirector
- Rudi MarienDirector
- Jose (Pepe) Calle GordoDirector
- Keith DawkinsDirector
- Victoria Carr-BrendelExecutive Officer
- Quan ZhouDirector
- Erik AmbleDirector
- Jan KeltjensDirector
- Offering amount
- $14.3M
- Amount sold
- $14.3M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.4MraisedAug 2017 · 14 investors · Other Health CareRule 506(b)
▶$9.4MraisedAug 2017 · 14 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ouyang XiangyuDirector
- Robert MitchellDirector
- Patrick van BenedenDirector
- Erik AmbleDirector
- Olivier LitzkaDirector
- Victoria Carr-BrendelExecutive Officer, Director
- Jan PensaertDirector
- Jan KeltjensDirector
- Peter WulffExecutive Officer
- Arnd KaltofenDirector
- Offering amount
- $9.4M
- Amount sold
- $9.4M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedAug 2016 · 11 investors · Other Health CareRule 506(b)
▶$10MraisedAug 2016 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jan PensaertDirector
- Raymond CohenDirector
- Peter WulffExecutive Officer
- Arnd KaltofenDirector
- Jan KeltjensDirector
- Patrick van BenedenDirector
- Ouyang XiangyuDirector
- Victoria Carr-BrendelExecutive Officer, Director
- Erik AmbleDirector
- Olivier LitzkaDirector
- Offering amount
- $23M
- Amount sold
- $10M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$26.5MraisedAug 2015 · 13 investors · Other Health CareRule 506(b)
▶$26.5MraisedAug 2015 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Arnd KaltofenDirector
- Raymond CohenDirector
- Erik AmbleDirector
- Jan KeltjensDirector
- Peter BarrettDirector
- Olivier LitzkaDirector
- Ouyang XiangyuDirector
- Patrick van BenedenDirector
- Victoria Carr-BrendelExecutive Officer, Director
- Hans-Reiner FigullaDirector
- Offering amount
- $26.5M
- Amount sold
- $26.5M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$73.4MraisedNov 2014 · 15 investors · Other Health CareRule 506(b)
▶$73.4MraisedNov 2014 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Erik AmbleDirector
- Patrick van BenedenDirector
- Ouyang XiangyuDirector
- Raymond CohenDirector
- Peter BarrettDirector
- Arnd KaltofenDirector
- Hans-Reiner FigullaDirector
- Jan KeltjensDirector
- David DrachmanExecutive Officer, Director
- Olivier LitzkaDirector
- Offering amount
- $73.4M
- Amount sold
- $73.4M
- First sale
- Jul 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Edwards Lifesciences34 shared keywords
Power19 shared keywordsPower builds a patient-friendly platform to discover and enroll in clinical trials, serving patients seeking access to research studies and researchers seeking to improve patient recruitment. The company operates in the healthcare technology and clinical research industry.
Boston Scientific14 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Companies competing with JenaValve for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does JenaValve do?
- JenaValve manufactures the Trilogy Transcatheter Heart Valve System, an FDA-approved device for treating severe aortic regurgitation in high-risk patients who cannot undergo surgical valve replacement. The company develops minimally invasive cardiac medical devices and related delivery systems for interventional cardiology.
- Who are JenaValve's investors?
- JenaValve's investors include Andera Partners, Bain Capital Life Sciences, VI Partners.
- How much funding has JenaValve raised?
- JenaValve has disclosed $315M raised across 8 rounds.
- Where is JenaValve headquartered?
- JenaValve is headquartered in Irvine, US.